Amy Tang is a Venture Partner at Qiming Venture Partners, a Beijing-based firm managing approximately $12 billion. See sector focus and contact routes.
Amy Tang is a Venture Partner at Qiming Venture Partners, a Beijing-based firm managing approximately $12 billion in assets, where she has served since December 2015 after spending 13 years as a Partner at Morningside Ventures directing its Beijing operations. She focuses on early-stage to growth-stage investments primarily in healthcare, biotechnology, artificial intelligence, enterprise software, and digital health, with a geographic focus on China. Her typical investment check ranges from $100,000 to $5.0 million, with a sweet spot near $1.5 million, and she participates in deals from seed through Series B. Notable portfolio companies include Hope Medicine, which raised a $56 million Series B in May 2021 and a $28 million Series B in February 2024 under her involvement. During her prior tenure at Morningside, she managed dozens of early-stage biotech portfolios that largely exited via IPOs or M&A with multiple returns. While her background includes regulatory and product management roles at GSK and a degree from Shenyang Pharmaceutical University, there is no publicly available record of distinctive point-of-view articles or public writing by Tang
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Beijing.
Investors like Amy Tang · Full investor directory · Investor access · Company funding database